Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Introducing intermediate filaments: from discovery to disease
John E. Eriksson, … , Hanna-Mari Pallari, Robert D. Goldman
John E. Eriksson, … , Hanna-Mari Pallari, Robert D. Goldman
Published July 1, 2009
Citation Information: J Clin Invest. 2009;119(7):1763-1771. https://doi.org/10.1172/JCI38339.
View: Text | PDF
Review Series

Introducing intermediate filaments: from discovery to disease

  • Text
  • PDF
Abstract

It took more than 100 years before it was established that the proteins that form intermediate filaments (IFs) comprise a unified protein family, the members of which are ubiquitous in virtually all differentiated cells and present both in the cytoplasm and in the nucleus. However, during the past 2 decades, knowledge regarding the functions of these structures has been expanding rapidly. Many disease-related roles of IFs have been revealed. In some cases, the molecular mechanisms underlying these diseases reflect disturbances in the functions traditionally assigned to IFs, i.e., maintenance of structural and mechanical integrity of cells and tissues. However, many disease conditions seem to link to the nonmechanical functions of IFs, many of which have been defined only in the past few years.

Authors

John E. Eriksson, Thomas Dechat, Boris Grin, Brian Helfand, Melissa Mendez, Hanna-Mari Pallari, Robert D. Goldman

×

Figure 1

Overview of the IF protein family.

Options: View larger image (or click on image) Download as PowerPoint
Overview of the IF protein family.
(A) All IF proteins share a tripartit...
(A) All IF proteins share a tripartite domain structure consisting of a highly conserved α-helical central rod domain flanked by variable N-terminal head and C-terminal tail domains. (B) Based on central rod domain amino acid sequences, net acidic charge, and secondary structure predictions, cytoskeletal IF proteins were grouped into 4 sequence homology classes (types I–IV). Nuclear IF proteins, the lamins, constitute a fifth class. The sixth class of IF proteins (also referred to as orphans), beaded filament structural protein 1 (Bfsp1; also known as filensin) and Bfsp2 (also known as phakinin and CP49), form highly specialized IFs found only in the lens of the eye. Based on their abilities to copolymerize, the IF proteins of the 6 types are further subdivided into assembly groups 1–3. NFL, NFM, NFH, low–, middle–, and high–molecular weight neurofilament subunits, respectively.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts